AU2021256222A1 - Prevention and treatment of organ injuries - Google Patents

Prevention and treatment of organ injuries Download PDF

Info

Publication number
AU2021256222A1
AU2021256222A1 AU2021256222A AU2021256222A AU2021256222A1 AU 2021256222 A1 AU2021256222 A1 AU 2021256222A1 AU 2021256222 A AU2021256222 A AU 2021256222A AU 2021256222 A AU2021256222 A AU 2021256222A AU 2021256222 A1 AU2021256222 A1 AU 2021256222A1
Authority
AU
Australia
Prior art keywords
infection
injury
use according
compound
respiratory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2021256222A
Other languages
English (en)
Inventor
Hans Fliri
Fashu MA
Ching-Pong Mak
Michael Peel
Dong Xiao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Farsight Medical Technology Shanghai Co Ltd
Original Assignee
Farsight Medical Technology Shanghai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Farsight Medical Technology Shanghai Co Ltd filed Critical Farsight Medical Technology Shanghai Co Ltd
Publication of AU2021256222A1 publication Critical patent/AU2021256222A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2021256222A 2020-04-15 2021-04-15 Prevention and treatment of organ injuries Abandoned AU2021256222A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2020/084820 2020-04-15
CN2020084820 2020-04-15
CNPCT/CN2021/081574 2021-03-18
CN2021081574 2021-03-18
PCT/CN2021/087501 WO2021209003A1 (en) 2020-04-15 2021-04-15 Prevention and treatment of organ injuries

Publications (1)

Publication Number Publication Date
AU2021256222A1 true AU2021256222A1 (en) 2022-10-06

Family

ID=78085285

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021256222A Abandoned AU2021256222A1 (en) 2020-04-15 2021-04-15 Prevention and treatment of organ injuries

Country Status (9)

Country Link
US (1) US12465629B2 (cg-RX-API-DMAC7.html)
EP (1) EP4135743A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023521161A (cg-RX-API-DMAC7.html)
KR (1) KR20230002589A (cg-RX-API-DMAC7.html)
CN (2) CN114245744A (cg-RX-API-DMAC7.html)
AU (1) AU2021256222A1 (cg-RX-API-DMAC7.html)
CA (1) CA3174545A1 (cg-RX-API-DMAC7.html)
TW (1) TWI889805B (cg-RX-API-DMAC7.html)
WO (1) WO2021209003A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3172535A1 (en) 2020-03-26 2021-09-30 Ching-Pong Mak Cyclophilin inhibitors and uses thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0194972B1 (en) 1985-03-11 1992-07-29 Sandoz Ag Novel cyclosporins
FI111730B (fi) 1990-11-02 2003-09-15 Novartis Ag Menetelmä ei-immunosuppressiivisen syklosporiinin valmistamiseksi
JPH08298986A (ja) * 1995-04-28 1996-11-19 Asahi Chem Ind Co Ltd ホスホリパーゼa2酵素
KR970064620A (ko) 1996-03-05 1997-10-13 임성기 사이클로스포린-함유 외용약제 조성물
ATE254630T1 (de) 1998-06-12 2003-12-15 Chem Ag C Cyclosporine
CN101068829B (zh) 2004-10-01 2012-05-30 西尼克斯公司 用于治疗和预防丙型肝炎病毒感染的3-醚和3-硫醚取代的环孢菌素衍生物
PT1802650E (pt) * 2004-10-01 2011-12-30 Scynexis Inc Derivados da ciclosporina 3-éter e 3-tioéter substituída para o tratamento e prevenção da infecção de hepatite c
WO2007041632A2 (en) * 2005-09-30 2007-04-12 Scynexis, Inc. Methods and pharmaceutical compositions for the treatment and prevention of hepatitis c infection
BRPI0708424A2 (pt) 2006-03-02 2011-05-31 Alexion Pharma Inc prolongamento da sobreviência de uma aloenxerto por inibição da atividade do complemento
CA2652662C (en) * 2006-05-19 2015-11-03 Scynexis, Inc. Methods for the treatment and prevention of ocular disorders
WO2008143996A1 (en) 2007-05-18 2008-11-27 Scynexis, Inc. New chemical processes
US8536114B2 (en) 2008-12-31 2013-09-17 Scynexis, Inc. Macrocycles
US9217015B2 (en) 2010-07-16 2015-12-22 S&T Global Inc. Cyclosporin derivatives for the treatment and prevention of a viral infection
MX350746B (es) * 2010-12-03 2017-09-14 Hebei Kunxiangjishi Pharmaceutical Tech Co Ltd Derivados de ciclosporina novedosos para el tratamiento y la prevención de una infección viral.
GB201217560D0 (en) 2012-10-02 2012-11-14 Mitopharm Ltd Novel cyclic depsipeptide compounds and their uses
TW201639873A (zh) 2015-01-08 2016-11-16 歐樂根公司 Mebmt側鏈已環化之環孢菌素衍生物
CN105983095B (zh) * 2015-02-15 2019-09-13 艾棣维欣(苏州)生物制药有限公司 一种呼吸道合胞体病毒疫苗及其制备方法与应用
CN106902346A (zh) 2015-12-23 2017-06-30 中美华世通生物医药科技(武汉)有限公司 药物组合物及其制药用途
CN106902347A (zh) * 2015-12-23 2017-06-30 中美华世通生物医药科技(武汉)有限公司 亲环孢素抑制剂的用途
GB201711749D0 (en) * 2017-07-21 2017-09-06 Cypralis Ltd Cyclosporin analogues and uses thereof
CN111449050A (zh) 2019-01-20 2020-07-28 睿诺医疗科技(上海)有限公司 环孢菌素类似物及其用途
CN116870135A (zh) * 2019-10-12 2023-10-13 睿诺医疗科技(上海)有限公司 肾毒素诱发的肾损伤的治疗和预防
CA3172535A1 (en) 2020-03-26 2021-09-30 Ching-Pong Mak Cyclophilin inhibitors and uses thereof
WO2021190603A1 (en) 2020-03-26 2021-09-30 Farsight Medical Technology (Shanghai) Co., Ltd. Cyclophilin inhibitors and uses thereof

Also Published As

Publication number Publication date
TW202143995A (zh) 2021-12-01
CA3174545A1 (en) 2021-10-21
CN113694177B (zh) 2022-06-17
EP4135743A4 (en) 2024-05-22
CN113694177A (zh) 2021-11-26
US20230181680A1 (en) 2023-06-15
WO2021209003A1 (en) 2021-10-21
KR20230002589A (ko) 2023-01-05
EP4135743A1 (en) 2023-02-22
TWI889805B (zh) 2025-07-11
US12465629B2 (en) 2025-11-11
CN114245744A (zh) 2022-03-25
JP2023521161A (ja) 2023-05-23

Similar Documents

Publication Publication Date Title
UA120756C2 (uk) Лікування внутрішньопечінкових холестатичних захворювань
US12465629B2 (en) Prevention and treatment of organ injuries
US20210393549A1 (en) New use of R-enantiomer of adrenergic beta 2 receptor agonists for treatment of inflammatory bowel disease and its extra intestinal manifestations
WO2012026928A1 (en) Use of glycyrrhetinic acid, glycyrrhizic acid and related compounds for prevention and/or treatment of pulmonary fibrosis
CN118806741A (zh) 二氢青蒿酸在制备预防或治疗急性肺损伤的药物中的应用
EP4346789B1 (en) Capsaicin derivatives in the treatment of idiopathic pulmonary fibrosis
US11534398B2 (en) Inhaled preparation of isoglycyrrhizic acid or salt thereof, and use in preparing drugs for treating respiratory system diseases
RU2451507C2 (ru) Лекарственное средство для лечения хронического обструктивного заболевания легких
US20260027094A1 (en) Use of pyridone derivative
US20260124182A1 (en) Nitazoxanide for the treatment of hepatic impairment
AU2010322066A1 (en) Treatment of acute exacerbation of asthma and reduction of likelihood of hospitalization of patients suffering therefrom
WO2025020917A1 (zh) 用于治疗脏器纤维化相关疾病的药物组合物和方法
CN106692976B (zh) P-糖蛋白抑制剂Gelucire44/14作为经口服的盐酸小檗碱吸收促进剂的应用
WO2025004042A1 (en) Nmdar antagonist for the treatment of inflammatory diseases in patients with depression comorbidity
EA052469B1 (ru) Лечение некистозных фиброзных (немуковисцидозных) бронхоэктазов
Qian et al. Effects of intraperitoneal (IP) different doses of ketamine on cognitive function in aged rats: 9AP6-8
KR20130038583A (ko) 소포체 스트레스 억제제를 유효성분으로 함유하는 급성 폐 손상의 예방 또는 치료용 약학 조성물
JP2002255805A (ja) 急性呼吸窮迫症候群の予防または治療用医薬組成物

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period